阿帕替尼联合调强放疗治疗胃癌的临床价值

目的探讨阿帕替尼靶向治疗联合调强放疗治疗胃癌的临床效果.方法66例胃癌患者,随机分为对照组和观察组,每组33例.对照组给予调强放疗,观察组给予阿帕替尼靶向治疗联合调强放疗.对比两组临床疗效、不良反应发生情况、生存时间、无进展生存时间.结果观察组疾病控制率72.73%高于对照组的42.42%,差异有统计学意义(P<0.05).观察组不良反应发生率为24.24%,与对照组的30.30%对比差异无统计学意义(P>0.05).治疗后,观察组生存时间为(1.52±0.33)年,长于对照组的(1.03±0.24)年,差异有统计学意义(t=6.898,P<0.05);观察组无进展生存时间为(0.69±0.14)年,长于对照组的(0.37±0.12)年,差异有统计学意义(t=9.969,P<0.05).结论胃癌患者采用阿帕替尼靶向治疗联合调强放疗能够改善临床疗效,提高患者生活质量.

Clinical value of apatinib combined with intensity-modulated radiotherapy in the treatment of gastric cancer

Objective To discuss the clinical effect of apatinib targeted therapy combined with intensitymodulated radiotherapy in the treatment of gastric cancer.Methods A total of 66 gastric cancer patients were randomly divided into control group and observation group,with 33 cases in each group.The control group received intensity-modulated radiotherapy,and the observation group received apatinib targeted therapy combined with intensity-modulated radiotherapy.The clinical efficacy,occurrence of adverse reactions,survival time and progression free survival time in the two groups was compared.Results The disease control rate 72.73% in the observation group was higher than 42.42% in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 24.24% in the observation group,which had no statistically significant difference compared with 30.30% in the control group(P>0.05).After treatment,the survival time was(1.52±0.33)years of the observation group,which was longer than(1.03±0.24)years of the control group,and the difference was statistically significant(t=6.898,P<0.05).The progression free survival time was(0.69±0.14)years of the observation group,which was longer than(0.37±0.12)years of the control group,and the difference was statistically significant(t=9.969,P<0.05).Conclusion Apatinib targeted therapy combined with intensity-modulated radiotherapy can improve the clinical efficacy of patients with gastric cancer,and improve their quality of life.